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ABSTRACT
Mutations in the UMOD gene coding for uromodulin cause
autosomal dominant tubulointerstitial kidney disease. Uromo-
dulin is known to regulate transport processes in the thick as-
cending limb, but it remains unknown whether UMOD
mutations are associated with functional tubular alterations in
the early phase of the disease. The responses to furosemide
and to a water deprivation test were compared in a 32-year-old
female patient carrying the pathogenic UMOD mutation
p.C217G and her unaffected 31-year-old sister. A single dose
of furosemide induced an intense headache with exaggerated
decrease in blood pressure (Δsyst: 30 versus 20 mmHg; Δdiast:
18 versus 5 mmHg) and body weight (Δ2.6 kg versus Δ0.9 kg
over 3 h) in the proband versus unaffected sib. The diuretic re-
sponse and the fall in urine osmolality were also more import-
ant and detected earlier in the affected sib. Water deprivation
led to increased plasma osmolality and urine concentration
in both siblings; however, the response to desmopressin was
attenuated in the affected sib. These data reveal that mutations
of uromodulin cause speciﬁc transport alterations, including
exaggerated response to furosemide and a failure to maximally
concentrate urine, in the early phase of the disease.
Keywords: autosomal dominant tubulointerstitial kidney
disease, furosemide, NKCC2, TAL, Tamm–Horsfall protein
INTRODUCTION
Uromodulin (Tamm–Horsfall protein) is exclusively pro-
duced in the epithelial cells lining the thick ascending limb
(TAL) of Henle’s loop and is the most abundant protein in
the normal urine. Evidence obtained from in vitro studies
and knock-out mouse studies have shown that uromodulin
protects against urinary tract infection and kidney stones,
and regulates transport systems operating in the TAL [1].
The latter include the sodium–potassium–chloride cotran-
sporter NKCC2 and the potassium channel ROMK, which
operate in parallel and are essential to reabsorb 25% of the
ﬁltered NaCl and to mediate the urinary concentrating
ability [2].
Mutations in the UMOD gene encoding uromodulin have
been shown to cause ‘medullary cystic kidney disease type 2’
(MCKD2; MIM 603 860), ‘familial juvenile hyperuricaemic
nephropathy’ (FJHN; MIM 162 000) and ‘glomerulocystic
kidney disease’ (GCKD; MIM 609 886) [3–5] which are col-
lectively referred to as uromodulin-associated kidney diseases
(UAKD). UAKD are autosomal dominant disorders character-
ized by hyperuricaemia and gout early in life, alteration of
urinary concentrating ability and tubulointerstitial ﬁbrosis
with occasional cysts at the cortico-medullary junction [1].
UAKD invariably lead to chronic renal failure during the third
to seventh decade of life [6]. There is no speciﬁc therapy to
slow renal disease progression, and most patients end up with
end-stage renal disease.
The fact that hyperuricaemia is the most consistent feature
observed in patients harbouring UMOD mutations has led
to suggestions that the disease causes a dysfunction of the
TAL, with NaCl loss and secondary reabsorption of uric acid
in the proximal tubule [6, 7]. This hypothesis has been sup-
ported by functional defects evidenced in the ﬁrst transgenic
mouse model of disease [8]. However, the existence of a specif-
ic dysfunction of the TAL as an early consequence of defective
uromodulin processing has not been evaluated in patients har-
bouring a pathogenic UMODmutation.
© The Author 2014. Published by Oxford University Press
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To investigate whether a pathogenic UMOD mutation is as-
sociated with functional alterations in the TAL in the early stage
of the disease, we compared the response to a furosemide test
and to a water deprivation test in a proband carrying a patho-
genic mutation of UMOD and her unaffected sister.
MATERIALS AND METHODS
The proband, a 32-year-old female harbouring a missense
(p.C217G) mutation in UMOD (III,2), and her 31-year-old
sister tested negative for the mutation (III,4) belong to a four-
generation family. The pathogenic nature of the p.C217G mu-
tation of UMOD was evidenced by the typical course of
UAKD observed in the other sister of the proband (III,3) who
reached end-stage renal disease at age 37 years (Figure 1A).
The proband and her unaffected sister had an estimated
glomerular ﬁltration rate (eGFR) according to the CKD-EPI
equation from the Chronic Kidney Disease - Epidemiology
Collaboration ≥60 mL/min/1.73 m2 at time of testing, and
none of them was diabetic. They were not taking any drugs, in-
cluding diuretics, allopurinol or antihypertensive medications.
The protocol was approved by the Ethical Committee of the
UCL Medical School (Brussels), and informed consent was
provided.
A 24-h urine collection was obtained in both sisters imme-
diately before the furosemide test. On the day of the furo-
semide test, a baseline clinical and biological evaluation was
performed at 9:30 AM, 4 h before giving a single oral dose of
80 mg furosemide. Baseline values for the furosemide test
(Figure 1B) correspond to a 3-h urine collection preceding im-
mediately the administration of furosemide. After furosemide
administration, urine samples were collected hourly during 3
h and analysed for Na+ and K+, creatinine, urea and uric acid
concentrations, osmolality and pH. Clinical and biological
evaluations were repeated at the end of the test (time +3 h;
Table 1). The following day (i.e. after 18 h of normal hydra-
tion), both individuals underwent an 8-h water deprivation
test, including a 30-min intravenous infusion of desmopressin
acetate (Minirin®, 0.3 μg/kg; Ferring AG, Baar, Switzerland)
after 6 h of water deprivation. Desmopressin (or deamino-8D-
arginine vasopressin, dDAVP) is a peptidic analogue of en-
dogenous antidiuretic hormone (ADH) with a higher afﬁnity
for V2 receptors and negligible vasopressive potential. A clin-
ical evaluation was performed hourly and plasma and urine
samples were taken every 2 h during the water deprivation and
1-h and 2-h after initiation of desmopressin perfusion. Dietary
intake was identical in the two sisters before the furosemide
test and throughout the water deprivation test.
RESULTS
The baseline osmolar balance in the two sisters immediately
before the functional tests was similar, thus allowing direct
inter-individual comparison of the responses to furosemide
and to water restriction (values for affected sib versus control sib:
24-h Na+ excretion: 228 versus 307 mmol; 24-h urea excretion:
29.1 versus 23.1 g; osmolar excretion rate: 779.2 versus 787.5
µosm/min; plasma renin activity: 1.1 versus 0.8 ng/mL/h; plasma
aldosterone: 0.31 versus 0.30 nM, respectively. Plasma ADH: <0.2
pg/mL in both sibs).
The furosemide test was poorly tolerated by the proband,
who reported intense headache, a severe drop in blood pressure
(Δ30/Δ18 mmHg versus Δ20/Δ5 mmHg in the unaffected sister)
and a weight loss of 2.6 kg (versus weight loss of 0.9 kg in the un-
affected sister) in 3 h (Table 1). After furosemide administration,
both siblings showed the expected increase in diuresis with con-
comitant fall in urine osmolality. However, the changes were
more important and were detected earlier in the proband, who
also showed a more pronounced and earlier increase of fractional
excretion of Na+ than the control sibling (Figure 1B).
The water deprivation test was well tolerated by both parti-
cipants. Blood pressure and weight remained constant during
all the procedures. As expected, water deprivation resulted in a
progressive increase in plasma osmolality with an increased
urine osmolality and a reduced urine ﬂow in both subjects
(Figure 1B). The response to desmopressin was normal in the
control sibling, with an increase in urine osmolality (from 983
to 1124 mOsm/kg H2O, 2 h after infusion), a decrease in urine
ﬂow (from 30 to 18 mL/h) and a decrease in plasma osmolal-
ity (from 298 to 295 mOsm/kg H2O). In contrast, the affected
sib showed a blunted increase in urine osmolality (from 834 to
869 mOsm/kg H2O), an increase in urine ﬂow (from 17.5 to
20 mL/h) and a paradoxical increase in plasma osmolality
(from 298 to 305 mOsm/kg H2O) (Figure 1B).
Pathology examination of the end-stage kidney biopsy of
patient III,3 (Figure 1C) revealed marked tubulointerstitial
lesions, with thickening of the tubular basement membrane
and abnormal processing and accumulation of uromodulin in
the tubular cells. Of note, there was no detectable immunos-
taining for NKCC2 in the biopsy.
DISCUSSION
In this study, we performed a sib-pair functional testing to
evaluate whether pathogenic mutations of UMOD are asso-
ciated with dysfunction of the TAL in the early phase of
UAKD. Our data reveal that the proband carrying an UMOD
mutation shows a clinically and biologically exaggerated re-
sponse to furosemide and a failure to maximally concentrate
urine after desmopressin administration. To the best of our
knowledge, this is the ﬁrst report of abnormal tubular func-
tional testing in a subject harbouring a pathogenic UMOD
mutation.
Several lines of evidence suggest that uromodulin plays an
important role in regulating NKCC2 and ROMK in the TAL
[9–11]. These two transport processes mediate the furosem-
ide-sensitive NaCl reabsorption and the generation of the
osmotic gradient that drives the urine concentrating ability.
Patients with UMOD mutations are characterized by an early
defect in urine concentration [3–5], which could be paralleled
with a discrete NaCl-losing phenotype explaining hyperuri-
caemia [6, 7]. Studies of mice harbouring a pathogenic muta-
tion of uromodulin revealed that the urinary concentrating
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F IGURE 1 : Pedigree of the family, UMODmutation, response to furosemide and water deprivation and end-stage kidney biopsy. A, Pedigree
of the family and UMODmutation. Individuals with a history of renal disease are depicted by black symbols. Circles denote females, squares
males. The proband carrying the UMODmutation (III,2) and her unaffected sister (III,4) are marked by an arrow and an arrowhead, respective-
ly. Individuals tested for mutation are tagged by an asterisk (*). Patient III,3 showed a typical course of uromodulin-associated kidney disease,
with hyperuricaemia at age 21 years and end-stage renal disease at age 37 years. Sequence analysis of the UMOD gene revealed a thymine to
guanine transition at nucleotide 794 resulting in the substitution of a well-conserved cysteine by a glycine at position 217 (p.C217G). Encoded
amino acid sequence is indicated above the DNA sequence. Mutated nucleotide is boxed. The mutation has been previously reported by Dahan
et al. [4]. B, Biological parameters at baseline and evaluation after furosemide administration and water deprivation with desmopressin perfu-
sion. The patient harbouring the UMODmutation is indicated by red dots and her unaffected sister by blue squares. Baseline values in the fur-
osemide test have been obtained from a 3-h urine collection immediately preceding furosemide administration. This same baseline diuresis has
been plotted in the water deprivation test curve. Urine and plasma osmolality values at time 0 of the water deprivation test were obtained from
urine and blood samples collected before the test. C, End-stage kidney biopsy from patient III,3 harbouring the p.C217G UMODmutation.
Haematoxylin–eosin staining (panel a) reveals interstitial ﬁbrosis and tubular atrophy with thickening of the tubular basement membrane
(inset, arrows). Immunostaining (panel b) reveals diffuse intracellular accumulation of uromodulin in a subset of cells lining enlarged tubules
(arrow) as well as cells displaying the normal apical staining for uromodulin (arrowhead). There is no detectable immunostaining for NKCC2
(panel c) in the kidney of patient III,3 compared with normal staining pattern (inset). Original magniﬁcations: a, ×350; b, ×200, c, ×700.
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defect precedes renal failure and is related to a speciﬁc defect
in the TAL [8]. The latter includes defective expression of
NKCC2 and other markers, secondary to the accumulation of
mutant uromodulin in the endoplasmic reticulum [8]. We
conﬁrm such lesions in the end-stage kidney biopsy of patient
III,3, showing extensive tubulointerstitial damage with abnor-
mal processing of uromodulin and loss of NKCC2 immunor-
eactivity.
The demonstration of an exaggerated response to furosem-
ide in the proband, despite the lower eGFR than her control
sister, is of particular interest. Since uromodulin expression
levels regulate NKCC2 activity [10, 11], it is conceivable that
the reduced trafﬁcking of native uromodulin in UAKD might
lead to a decreased amount of active NKCC2 on the apical cell
membrane. This effect would be ampliﬁed by the fact that
disease-causing UMOD mutations also lead to decreased
surface expression of ROMK [9]. The paradoxically increased
response to furosemide, as observed here, might therefore in-
dicate that there is still sufﬁcient NaCl uptake capacity (e.g.
due to hyperactivated residual NKCC2) to maintain a steady-
state in the early stage of disease. Administration of furosem-
ide may disrupt this equilibrium, by inhibiting active NKCC2
transporters with no immediately available compensation in
other tubule segments. The normal serum uric acid levels
(Table 1) and the slightly higher uric acid fractional excretion
in the proband (5.9 versus 5.1% in the healthy sib calculated
from the baseline 3-h urine collection) may indeed suggest a
maintained sodium balance by residual TAL function without
proximal compensatory adaptation.
Alternatively, the exaggerated response to furosemide in the
proband with early UAKD could unmask a shift of steady-
state NaCl reabsorption inside the TAL. Based on functional
and anatomical differences, the TAL segment could indeed be
subdivided into a cortical (cTAL) and a medullary (mTAL)
portion. The cTAL, which lies in an environment isosmotic to
the plasma, is responsible for the majority of NaCl reabsorp-
tion and is the true ‘diluting segment’ of the nephron [12, 13].
In the rat kidney, two different cell types coexist in the TAL:
cells with a smooth surface and a dense subapical NKCC2-
containing vesicle pool, which predominate in the mTAL, and
cells with a rough surface and a much less abundant vesicle
system, which largely dominate in the cTAL [14]. Although
human UMOD transcript levels have been found to be quite
similar in mTAL and cTAL [15], human uromodulin protein
levels were 4-fold greater in the TAL-enriched outer medulla
than in the cortex by immunoblotting [16]. In healthy indivi-
duals, steady-state NaCl reabsorption is probably achieved by
the early part of cTAL, leaving a ‘physiological reserve’ in the
F IGURE 1 : Co n t i n u e d
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late part of the cTAL [12]. In the proband with early UAKD, a
reduced function of NKCC2 in mTAL could be compensated
by a larger implication of the cTAL, possibly spared from the
transport alterations associated with UAKD. Thus, a shift of
NaCl reabsorption to downstream/late part of the cTAL may
have used up the ‘physiological reserve’ in the affected sib,
which could then contribute to the differential response to fur-
osemide. The fact that, in contrast to the control sib, the
proband was unable to lower its urinary sodium concentration
below plasma sodium (data not shown) might further indicate
that the diluting function of the TAL was completely abolished
by furosemide. Taken together, these data indicate that the re-
sponse to furosemide in UAKD patients is diphasic, with an
exaggerated response in early disease and an anticipated loss
of response as predicted by the loss of NKCC2 in end-stage
kidney. Loop diuretics in these patients should thus be
managed with great caution.
At baseline, the proband showed a trend for increased
plasma osmolality contrasting with lower urine osmolality,
compatible with a slight alteration of water homeostasis.
The observation of a preserved response to water deprivation
followed by a blunted response to desmopressin may again
indicate a reduced ‘physiological reserve’ of the urinary con-
centrating ability in early UAKD. The normal response of
the proband to water deprivation is distinct from the severe
nephrogenic diabetes insipidus observed in the transgenic
mutant mouse model [8]. The difference is probably due to
the fact that the tubular and interstitial lesions observed in the
patient are less severe than in the transgenic mice analysed at a
late stage of the disease. Additionally, the water restriction test
challenges mostly the inner medulla with its ADH-sensitive
urea transporters in the terminal collecting duct, where uro-
modulin expression is absent [13]. Possible explanations for
the blunted response to desmopressin include (i) a failure to
increase or maintain interstitial medullary hyperosmolality
and/or (ii) a decreased response to desmopressin. A less active
osmolar gradient generator, namely NKCC2 transporter, or a
leaky TAL allowing water inﬂux into the interstitium or NaCl
backleak into the lumen could underlie the former hypothesis.
Considering the interactions of uromodulin with NKCC2 and
the physical properties (including water impermeability) of
uromodulin polymers formed under speciﬁc ionic conditions
[1], an altered interstitial osmolality could be very well
explained by a reduced excretion of uromodulin. In fact, the
Umod KO mice showed no increase in pNKCC2 after stimula-
tion with dDAVP, suggesting that uromodulin is important for
the TAL sensitivity to vasopressin [10].
The main limitations of this study include the small num-
ber of siblings involved and the lack of histopathology data in
the early stage of disease. However, we feel that these observa-
tions give insights into the biology of uromodulin and the
pathophysiology of UAKD. We investigated a patient with pre-
clinical disease, with presumably limited interstitial inﬂamma-
tion/ﬁbrosis (normal urinary sediment), and an unaffected
sibling of the same gender and similar age. The deleterious
effect of the mutation was evidenced by the end-stage kidney
biopsy of a third sibling.
In conclusion, our study suggests that, in the early phase of
UAKD, the lack of functional uromodulin leads to a discrete
dysfunction of the TAL, with maintenance of a precarious
clinical equilibrium that can be disturbed by speciﬁc testing.
As the disease progresses, the aggravation of the tubulointersti-
tial lesions leads to overt tubular dysfunction and compensa-
tory mechanisms, culminating with chronic kidney disease.
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Table 1. Clinical and biological response to furosemide in the proband and the unaffected sibling
Proband (III,2) Unaffected sib (III,4)
Baseline Furosemide + 3 h Baseline Furosemide + 3 h
Weight (kg) 76.1 73.5 81.1 80.2
Blood pressure (mmHg) 140/90 110/72 135/80 115/75
eGFR (CKD-EPI; mL/min/1.73 m2) 60 60 99 99
Plasma urea (mg/dL) 45 43 25 23
Plasma sodium (mmol/L) 141 138 139 138
Plasma potassium (mmol/L) 4.4 3.7 3.8 3.8
Plasma uric acid (mg/dL) 6.3 6.3 6.4 6.4
Plasma osmolality (mOsm/L) 298 298 287 288
Plasma bicarbonate (mmol/L) 27.5 29.5 22.5 27.5
The parameters were similarly recorded 4 h before (Baseline) and 3 h after furosemide administration (Furosemide + 3 h).
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